atezolizumab + tazemetostat

Atezolizumab + tazemetostat is an investigational combination therapy consisting of **atezolizumab**, a humanized monoclonal antibody that targets **programmed death-ligand 1 (PD-L1)** to block its interaction with PD-1 and B7.1 and thus inhibits immune checkpoint signaling, and **tazemetostat**, an oral small molecule inhibitor of **enhancer of zeste homolog 2 (EZH2)**, a histone methyltransferase involved in epigenetic gene silencing. This combination is designed to enhance anti-tumor immune response by simultaneously reprogramming the tumor microenvironment epigenetically and relieving immune suppression. It has been primarily studied in patients with relapsed/refractory **diffuse large B-cell lymphoma (DLBCL)** and is under investigation for other solid tumors such as metastatic non-small cell lung cancer (NSNSCLC) as part of immunotherapy combination studies[1][4][5][6].

Other names

atezolizumab and tazemetostat combination